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Insights into the origin of DNA methylation
differences between monozygotic twins
discordant for schizophrenia
Melkaye G. Melka1, Christina A. Castellani1, Richard O’Reilly2 and Shiva M. Singh1*
Abstract
Background: DNA methylation differences between monozygotic twins discordant for schizophrenia have been
previously reported. However, the origin of methylation differences between monozygotic twins discordant for
schizophrenia is not clear. The findings here argue that all DNA methylation differences may not necessarily
represent the cause of the disease; rather some may result from the effect of antipsychotics.
Methods: Methylation differences in rat brain regions and also in two pairs of unrelated monozygotic twins
discordant for schizophrenia have been studied using genome-wide DNA methylation arrays at Arraystar Inc.
(Rockville, Maryland, USA). The identified gene promoters showing significant alterations to DNA methylation
were then further characterized using ingenuity pathway analysis (Ingenuity System Inc, CA, USA).
Results: Pathway analysis of the most significant gene promoter hyper/hypomethylation revealed a significant
enrichment of DNA methylation changes in biological networks and pathways directly relevant to neural development
and psychiatric disorders. These included HIPPO signaling (p = 3.93E-03) and MAPK signaling (p = 4.27E-03) pathways
involving hypermethylated genes in schizophrenia-affected patients as compared to their unaffected co-twins. Also, a
number of significant pathways and networks involving genes with hypomethylated gene promoters have been
identified. These included CREB signaling in neurons (p = 1.53E-02), Dopamine-DARPP32 feedback in cAMP signaling
(p = 7.43E-03) and Ephrin receptors (p = 1.13E-02). Further, there was significant enrichment for pathways involved in
nervous system development and function (p = 1.71E-03-4.28E-02).
Conclusion: The findings highlight the significance of antipsychotic drugs on DNA methylation in schizophrenia
patients. The unique pathways affected by DNA methylation in the two pairs of monozygotic twins suggest that
patient-specific pathways are responsible for the disease; suggesting that patient-specific treatment strategies may be
necessary in treating the disorder. The study reflects the need for developing personalized medicine approaches that
take into consideration epigenetic variations between patients.
Background
Epigenetic modifications may affect gene expression
without the existence of changes in DNA sequence [1].
They are known to affect a number of neurological disor-
ders [2, 3] including psychosis [4]. Specifically, DNA
methylation is known to affect gene expression via tran-
scriptional regulation [5]. Further, a number of environ-
mental factors may affect gene-specific DNA methylation,
and this alteration may be maintained during genetic
transmission through mitosis and meiosis [6]. These dy-
namic changes may explain the discordance of monozy-
gotic twins [7] that are considered genetically identical. In
fact, several studies have reported methylation differences
between monozygotic twins discordant for a variety of dis-
orders including schizophrenia [8, 9]. Interestingly, hyper-
methylation has been reported to affect genes that have
been implicated in psychiatric disorders [10]. These results
have been used to argue that aberrations in gene specific
DNA methylation must represent, at least, one of the con-
tributing mechanisms in the manifestation of psychiatric
disorders [10]. The epigenetic float and drift during devel-
opment can be stochastic, caused by environmental
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factors or (most likely) the result of a combination of
the two [11]. Although the involvement of stochastic
processes have been difficult to establish, a number of
environmental agents are known to affect epigenetic-
dependent disease phenotypes in a number of disorders.
An example of this includes the hypermethylation of
tumor suppressor genes in a variety of cancers [12]. Such
results question the cause of differentially methylated
psychosis-related genes in monozygotic twins discordant
for psychosis. There is a possibility that the observed
methylation difference is caused by (still unknown) envir-
onment factors, such as drugs. This suggests that some of
the observed differential methylation between monozy-
gotic twins discordant for this disorder may not necessar-
ily be the cause of the disorder in the affected twin.
In this report, we discuss two complementary sets of
results. The first deals with identification of hypermethy-
lation/hypomethylation of a set of genes in the affected
individuals of two sets of unrelated monozygotic twins
discordant for schizophrenia. The results support the lit-
erature that monozygotic twins do differ in the DNA
methylation status of their genes and the hypermethy-
lated/hypomethylation genes may take part in pathways
affecting psychiatric disorders. Our second set of results
shows that an antipsychotic drug (Olanzapine) treatment
may cause its effect via hypermethylation/hypomethy-
lation of a number of genes that have been implicated
in psychosis [13]. Interestingly, several genes affected
by hyper/hypomethylation in the second study are
psychosis related genes. Taken together, the results
offer novel insight into the epigenetic cause(s) and
treatment of psychotic disorders. It forms the focus of
this report.
Methods
This study involves two psychosis-affected monozygotic
twins and their healthy co-twins (n = 4). All subjects
gave written informed consent to participate in the study
and contributed whole blood samples for DNA analysis.
The demographic information and the medication status
of the affected twins are described elsewhere [14]. Gen-
omic DNA was extracted from the blood samples using
the PerfectPure DNA Blood Kit, following the manufac-
ture’s protocol (http://www.5prime.com). Samples of
genomic DNA were sonicated to random fragments in a
size range of about 200–1000 bp. Immunoprecipitation
of methylated DNA fragments was performed using Bio-
magTM magnetic beads coupled mouse monoclonal anti-
body against 5-methylcytidine. The precipitated DNA
was eluted and purified by phenol chloroform extraction
and ethanol precipitation. The total input and immuno-
precipitated DNA were labeled with Cy3- and Cy5-
labeled random 9-mers, respectively, and hybridized to
the NimbleGen Human DNA Methylation 3x720K
Promoter Plus CpG Island Array, which is a multiplex
slide with 3 identical arrays per slide and each array
contains 27,728 CpG Islands annotated by UCSC and
22,532 well-characterized RefSeq promoter regions
(from about −2,440 to +610 bp of the TSSs) totally cov-
ered by ~720,000 probes. Scanning was performed with
the Axon GenePix 4000B microarray scanner. This
methylation protocol was carried out at ArrayStar Inc
(Rockville, MD, USA).
The details of olanzapine treatment of experimental rats
are described fully elsewhere [15]. Briefly, adult male Spra-
gue–Dawley rats of 12 weeks of age (250 – 300 g) were
purchased from Charles River, PQ, Canada. Rats were
weighed and divided into two treatment groups (olanzapine
treated and control) with comparable means of weight. Rats
received injections of olanzapine (Zyprexa, Lilly, IN,
USA; 2.5 mg/kg, i.m.; n = 8) or vehicle (phosphate buff-
ered saline (PBS); n = 8) between 1:30 and 3:00 pm daily
for 19 days.
Methylation enrichment and peak-finding
Raw data generated from scans were normalized (log2-
ratio). It followed Median centering, quantile normaliza-
tion and linear smoothing using Bioconductor packages
Ringo, limma, and MEDME. The results were used in a
sliding-window (750 bp) peak-finding algorithm provided
by NimbleScan v2.5 (Roche-NimbleGen). A one-sided
Kolmogorov-Smirnov (KS) test is applied to determine
whether the probes are drawn from a significantly more
positive distribution of intensity log2-ratios than those in
the rest of the array. Each probe receives a log10 p-value
score from the windowed KS test around that probe. If sev-
eral adjacent probes rise significantly above a set threshold,
the region is assigned to an enrichment peak (EP). The
peak data files are generated from the p-value data files.
NimbleScan detects peaks by searching for at least two
probes above a p-value minimum cutoff (−log10) of 2.
Peaks within 500 bp of each other are merged. Further de-
tails of the quality control and normalization procedures in
the twins and rat datasets are presented elsewhere [14, 15].
The genome-wide methylation analysis was applied to two
unrelated pairs of monozygotic twins discordant for
schizophrenia. For microarray data of replicate samples, a
T-test was performed between different groups to calculate
the p values for each probe. Probes with p < 0.05 were
identified as differentially methylated probes, which were
further analyzed to find Differentially Methylated Regions
(DMR). Finally, we have applied a more stringent threshold
of significant differences in DNA methylation (p < 0.001) to
filter the genes affected by DNA methylation changes in
their promoter regions. It allowed identification of bio-
logically relevant genes showing hypermethylation in
schizophrenia-affected twins as compared to their un-
affected co-twin.
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DEP analysis using M’ method
When comparing two groups’ differentially enriched re-
gions, the average of the log2-ratio values for each group
(Experiment and Control) was obtained and M’ value
(defined by the following equation) was calculated for
each probe. Then, the NimbleScan sliding-window peak-
finding algorithm was rerun on the data to find the dif-
ferential enrichment peaks (DEP).
M’ ¼ Average log2MeDIPE=InputEð Þ
‐ Average log2MeDIPC=InputCð Þ
The differential enrichment peaks (DEP) called by the
NimbleScan algorithm were filtered according to the fol-
lowing criteria:
i). At least one of the two groups has a median (log2
MeDIP/Input) > =0.3 and M’ > 0.
ii). At least half of probes in a peak may have coefficient
of variability (CV) < = 0.8 in both two groups.
Pathway analysis
Genes affected by DMRs were analyzed with Ingenuity
Pathway Analysis (IPA) for each patient. Also, the genes
identified were matched with genes in the schizophrenia
gene database (www.szgene.org). Top pathways and net-
works related to the two pairs are reported here. Finally,
we have assessed whether the genes affected by pro-
moter hyper/hypomethylation were among the psychosis
related genes listed in Gemma (www.chibi.ubc.ca/Gemma/
home.html). Furthermore, IPA was also used to identify
the most significant pathways and networks affected by
hyper/hypomethylation in the rat brain regions. Similarities
and differences between pathways and networks affected
by hyper/hypomethylation in the twins and in rat brain re-
gions (hippocampus and cerebellum) exposed to a thera-
peutic dose of an antipsychotic drug (olanzapine) were
assessed (n = 8). Moreover, psychosis related genes showing
methylation differences between schizophrenia-affected
twins and healthy co-twins were identified.
Results
A. Monozygotic twins discordant for schizophrenia – Twin
Pair 1
Pathways and networks affected by hypermethylation in
the patient
Hypermethylated genes in the affected as compared to
unaffected twin of twin pair 1 were analyzed with In-
genuity Pathway Analysis (IPA). This analysis identified
a number of relevant pathways and networks. These in-
cluded HIPPO signaling (p = 3.93E-03) and MAPK sig-
naling (p = 4.27E-03) canonical pathways (Table 1). Also,
the diseases and disorders affected by hypomethylation
of genes in this patient included developmental and
hereditary disorders (p = 3.56E-03–4.72E-02). The most sig-
nificant network affected by hypermethylation of genes in
the patient was a cellular growth, proliferation and cellular
movement and development network (score = 131) (Fig. 1).
Table 1 Most significant pathways and networks identified by IPA
of genes showing significant (p< 0.001) promoter
hypermethylation (A) and hypomethylation (B) of the schizophrenia
affected vs. healthy monozygotic twins in twin pair 1
A)
Canonical Pathways P-value Ratioa
HIPPO signaling 3.93E-03 4/85 (0.047)
MAPK Signaling 4.27E-03 4/87 (0.046)
Molecular and Cellular Functions
Cell Cycle, DNA Replication,
Recombination
1.69E-04–1.51E-02 6
Cellular development, growth
and proliferation
1.16E-03–4.45E-02 24
Cell Death and Survival 1.67E-03–4.54E-02 22
Diseases and Disorders
Developmental disorder 3.56E-03–4.72E-02 16
Hereditary disorder 3.56E-03–2.99E-02 22
Organismal injury and abnormalities 3.56E-03–4.91E-02 45
Most Significant Networks #of molecules
Cellular Growth, Proliferation,
Cellular movement & development
131
Cell Death and Survival, Cellular
movement
69
B)
Canonical Pathways P-value Ratioa
Dopamine-DARPP32 feedback in
cAMP signaling
7.43E-03 6/157 (0.038)
Calcium Signalling 1.08E-02 6/170 (0.035)
Ephrin Receptor Signalling 1.13E-02 6/172 (0.035)
Molecular and Cellular Functions
Gene expression 3.75E-04–4.97E-02 37
Cellular Assembly and Organization 1.15E-03–4.61E-02 22
Small Molecule Biochemistry 3.39E-03–4.51E-02 16
Lipid Metabolism 3.39E-03–3.69E-02 6
Diseases and disorders # of molecules
Metabolic disease 3.38E-04–4.28E-02 17
Endocrine system disorders 1.95E-04–4.42E-02 21
Nervous system development
and function
1.71E-03–4.28E-02 3
Most Significant Networks
Cell-mediated Immune Response,
Cellular Movement
60
Cell Cycle, Cellular Development 56
aThe number of molecules that reach the threshold of significant methylation
difference between twins
(Peak score > =3.1)
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Pathways and networks affected by hypomethylation in the
patient
Among the most significant canonical pathways identified
using the list of genes that showed promoter hypomethyla-
tion in the patient in twin pair 1 were dopamine-DARPP32
feedback in cAMP signaling (p = 7.43E-03), calcium signal-
ing (p = 1.08E-02) and ephrin receptor signaling (p = 1.13E-
02) (Fig. 2). Also, the most significant molecular and
cellular functions revealed using the same list of genes
were gene expression (p = 3.75E-04–4.97E-02), cellular
assembly and organization (p = 1.15E-03–4.61E-02),
lipid metabolism (p = 3.39E-03–3.69E-02), and small
molecule biochemistry (p = 3.39E-03–4.51E-02). There
was also clear enrichment for a pathway involved in
nervous system development and function (p = 1.71E-03–
4.28E-02) (Table 1).
B. Monozygotic twins discordant for schizophrenia – Twin
Pair 2
Pathways and networks affected by hypermethylation in
the patient
Table 2 presents that the triacylglycerol biosynthesis
(p = 2.94E-03) pathway was affected by genes that showed
promoter hypermethylation in the patient as compared to
their unaffected co-twin. These differences also affected
gene expression (p = 5.79E-06–3.62E-02) and molecular
Fig. 1 Cellular growth, proliferation, cellular movement & development (genes hypermethylated in the schizophrenia patient in Twin Pair 1 as
compared to unaffected co-twin)
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transport and protein trafficking (p = 4.01E-03–4.39E-03)
functions. The most significant disorders implicated,
similarly to twin pair 1, were developmental and her-
editary disorders (p = 9.84E-04–4.10E-02), organismal
injury and abnormalities (p = 4.41E-04–4.40E-02), and
involved aberrations in gene expression (p = 5.79E-06–
3.62E-02). The top network affected by hypermethyla-
tion of genes included cell death and survival, cellular
growth and proliferation, and cell morphology (peak
score = 47) (Fig. 3).
Pathways and networks affected by hypomethylation in the
patient
It is apparent from the results included in Table 2 that pro-
moter hypomethylation of genes in the patient significantly
affects canonical pathways involving glutamate receptor
signaling and CREB signaling in neurons (p = 1.53E-02)
(Fig. 4), as well as molecular and cellular functions, specif-
ically cell signalling (p = 4.34E-06–4.51E-02), nucleic acid
metabolism (p = 4.34E-06–4.51E-02), and small molecule
biochemistry (p = 4.34E-06–4.51E-02).
Shared pathways between olanzapine treated rat brains
and affected twins
A therapeutic dose of olanzapine caused hyper- and
hypo-methylation of genes involved in several psychosis
related pathways and networks. Further details on the
data are available on Melka et al. [15]. Intriguingly, some
of the most significant pathways identified in monozy-
gotic twins discordant for schizophrenia were also af-
fected in rat brain regions. The common pathways and
networks affected by olanzapine-induced hypermethyla-
tion and the twin patients (exposed to antipsychotic
drugs) included the MAPK signaling pathway (p = 1.59E-
03), a cell death, cellular growth and proliferation net-
work (peak score = 24) (Table 1, Additional file 1: Tables
S1 and S2), and a molecular transport and protein traf-
ficking (peak score = 12) network (Table 2, Additional
file 1: Table S2). Similarly, hypomethylation of genes in
both sets of results (i.e. olanzapine treated rat brains and
the twin study) affected calcium signaling (p = 5.92E-03)
(Table 1, Additional file 1: Table S1). We have noted,
despite the fact that there are some commonly affected
Fig. 2 Ephrin receptor signaling pathway (genes hypomethylated in the schizophrenia patient of Twin Pair 1). The genes affected by methylation
are highlighted in purple
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pathways and networks between the two sets of results,
that the individual genes involved in hyper/hypomethyla-
tion are not identical in rat brains and twin patients.
However, both sets of results show methylation changes
on psychosis related genes (Fig. 5).
Discussion
The genome-wide methylation results on two pairs of
monozygotic twins discordant for schizophrenia offer a
number of insights. First, the twins do differ in methyla-
tion patterns. It follows similar conclusions in a number
of reports [16, 17]. Interestingly, these differences appear
to accumulate over time, and may account for the chan-
ging transcriptome [12] as well as the discordance of
monozygotic twins for a variety of phenotypes and disor-
ders, particularly psychosis.
Second, the genes affected by hyper/hypomethylation
of promoters are not random. Several genes with pro-
moter hyper/hypomethylation in schizophrenia twins
were found to be psychosis related (Fig. 5, Additional file
2: Table S3). Predominantly, these genes appear to play a
role in pathways and networks that are relevant in the
context of the disease in question. Such conclusions follow
a number of reports where discordance for psychosis has
been suggested to involve differences in methylation [18].
This study has shown hyper- and hypo-methylation of
genes affecting psychotic relevant pathways such as HIPPO
signaling and Ephrin signaling, respectively, in twin pair 1.
Similarly, hypermethylation of genes affecting Triacylglyc-
erol Biosynthesis which had been associated with psych-
osis [19, 20]; and hypomethylation of genes affecting
glutamate and CREB signaling pathways in twin pair 2,
which are also associated with psychosis [21]. Interest-
ingly, neural stem cell proliferation has been previously
associated with altered methylation of CREB [22]. In
both cases, the identified pathways are involved in dis-
orders that may affect the development and course of
psychosis. Further, it has been shown that epigenetic
aberrations including methylation, may lead to disturb-
ance of inhibitory activity and cortical associative func-
tions [23]. Interestingly, hippocampal functions and
cognitive performance could be influenced by epigenetic
regulation of genes implicated in glutamate signaling
[24]. The results support the relevance of developing
personalized medicine not only with respect to genetic
variations but also to epigenetic variations.
Third, the two twin pairs representing discordance
for schizophrenia in two unrelated families show over-
laps in pathways and interactions identified in the two
patients. Of special interest to our findings are net-
works affected by hypermethylation of genes affecting
Cell Death and Survival, Cellular Growth and Cellular
Movement (Tables 1 and 2) in both schizophrenia af-
fected patients. Similarly, genome-wide DNA methyla-
tion variations between adolescent monozygotic twins
were associated with enrichment in pathways and net-
works involved in cellular growth and proliferation
[25] and these significant differences in methylation of
monozygotic twins have been associated with psych-
osis [26].
Table 2 Most significant pathways and networks identified by
IPA of genes showing significant (p < 0.001) promoter
hypermethylation (A) and hypomethylation (B) of the
schizophrenia affected vs. healthy monozygotic twins in twin
pair 2
A)
Canonical Pathways P-value Ratioa
Triacylglycerol Biosynthesis 2.94E-03 4/33 (0.121)
Phosphatidylglycerol
Biosynthesis II
3.39E-03 3/17 (0.176)
Molecular and Cellular Functions
Gene Expression 5.79E-06–3.62E-02 53
Cellular Movement 9.84E-04–4.83E-02 19
Molecular transport and
protein trafficking
4.01E-03–4.39E-03 16
Diseases and disorders
Developmental disorder 9.84E-04–4.10E-02 36
Hereditary disorder 9.84E-04–3.77E-02 46
Most Significant Networks # of molecules
Cell Death and Survival,
Cellular Growth
47
Cellular Movement,
Immune Cell Trafficking
45
B)
Canonical Pathways P-value Ratioa
Glutamate Receptor Signaling 1.05E-02 4/56 (0.071)
CREB Signalling in Neurons 1.53E-02 7/169 (0.041)
Molecular and Cellular
Functions
Cell Signalling 4.34E-06–4.51E-02 18
Nucleic Acid Metabolism 4.34E-06–4.51E-02 16
Small Molecular Biochemistry 4.34E-06–4.51E-02 29
Diseases and disorders
Cell death and survival 3.55E-06–4.76E-02 141
Inflammatory disease 3.35E-03–4.59E-02 18
Most Significant Networks # of molecules
Cellular Movement, Immune
Cell Trafficking
64
Cell Death and Survival, Cell
Cycle, Embryonic Development
45
Cellular Movement, Cellular
Growth and Proliferation,
cell morphology
44
aThe number of molecules that reach the threshold of significant methylation
difference between twins
(Peak score > =3.1)
Melka et al. Journal of Molecular Psychiatry  (2015) 3:7 Page 6 of 10
Finally, it is logical to ask the question regarding the
cause of these differences. Is DNA methylation causing
the disorder or is this due to other factors? To the best of
our understanding this question has not been addressed
satisfactorily, which is the focus of this section of the dis-
cussion. As mentioned, we have generated data on rats to
further address this question. It involves the use of a rat
model where a therapeutic dose of olanzapine is adminis-
tered [13]. The results show that olanzapine affects
methylation of a large number of genes [13]. They affect
pathways and interactions that are compatible with psych-
osis. For example, we report epigenetic alterations of the
dopaminergic system [27, 28] and serotonin transporter
gene promoters [29], which have been evident in major
psychiatric disorders, including schizophrenia [30]. In par-
ticular, hyper/hypomethylation in rat brain regions support
the dopamine hypothesis of schizophrenia reflecting the ef-
fect of olanzapine [13]. This argument has been supported
by two observations. First, common networks such as cellu-
lar growth and cellular movement were affected by hyper/
hypomethylation in both patients. Second, psychotic-
relevant pathways such as the Dopamine-DARPP32
feedback in cAMP signaling were also affected by
olanzapine-induced methylation [15]. Interestingly, those
pathways have also been observed in the current twin
study. We acknowledge that these results are based on
Fig. 3 Cell death and survival, cellular growth and proliferation, cell morphology (genes hypermethylated in the schizophrenia patient of Twin Pair 2)
Melka et al. Journal of Molecular Psychiatry  (2015) 3:7 Page 7 of 10
only two pairs of MZ twins and there may be a need to
confirm the results using additional methods such as
bisulphite sequencing. However, the uniformity of the re-
sults being reported prompted us to ask the question,
could methylation changes in the affected twin be caused
by antipsychotic drugs that have been administered during
the course of the management of their psychotic symp-
toms? We conclude by suggesting that this possibility can-
not be ruled out. The implication is that studies on DNA
methylation on psychiatric disorders where patients are
often on medication should be interpreted carefully. More
importantly, it may be premature for published reports to
conclude that epigenetic changes are causes of psychosis
in patients.
Conclusion
First, DNA methylation differences between monozy-
gotic twins discordant for schizophrenia revealed com-
mon networks affected in both unrelated twin pairs
suggesting that those networks may underlie the cause
Fig. 4 CREB signaling in neurons (genes hypomethylated in the schizophrenia patient of Twin Pair 2)
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of the disease. Although there exist common pathways,
this study also showed that unique genes were affected
in each pair of twins suggesting that the aetiology and/or
the pathophysiology of the diseases may involve unique
(patient-specific) genes entailing the need for personal-
ized medicine in treating the disorder. Importantly, these
patient-specific genes together with the observed effect
of antipsychotics on genes in rat brains as compared to
monozygotic twins corroborate the known heteroge-
neous nature of the disorder. Second, the results also
showed patient-specific pathways, which support previ-
ous findings highlighting that the effects of antipsychotic
drugs administered to patients may have caused at least
some of the hyper/hypomethylation differences. These
results reflect the fact that personalized medicine is not
only necessary for patients of wider genetic variations
but also for patients of epigenetic variations such as
DNA methylation. The findings could be relevant for fu-
ture therapeutic investigation of complex disorders in
addition to schizophrenia.
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